Syntegon reported first-half 2026 group sales of Euro 883 million, up 7% year-on-year, with adjusted EBITDA rising 16% to Euro 148 million. The adjusted EBITDA margin expanded to 16.8%, up 130 basis points versus the first half of 2025. Order intake reached Euro 964 million, with a book-to-bill ratio of 1.09 and a record order backlog of Euro 1.3 billion.
“Our first-half 2026 results underline the positive impact of our strategy and the strength of Syntegon’s market position,” said Torsten Türling, chief executive officer of Syntegon. “Our Pharma business remains our strongest growth engine. We achieved major new customer wins and market share gains in the expanding biologics market globally and in the United States in particular.”
“Our first-half results demonstrate Syntegon’s strong operating leverage. Adjusted EBITDA increased more than twice as fast as sales, taking the margin to 16.8%,” added Eros Carletti, chief financial officer of Syntegon. “This reflects the stronger earnings contribution from Pharma, operational discipline and continued improvements in project execution. Our solid order book provides a strong foundation for continued profitable growth and cash generation.”
Pharma business achieves double-digit sales growth
According to the company, the pharmaceutical and biotech industries continue to benefit from structural growth drivers, including the expansion of biologics and injectable medicines and growing demand for more flexible and highly automated pharmaceutical production. Syntegon’s Pharma sales increased by 14% in the first half of 2026, making the business the strongest contributor to Group growth. Demand remained strong for aseptic Fill & Finish and isolator-equipped line solutions, supported by continued investment in biologics and injectable medicines as well as increasingly stringent regulatory requirements. Pharma Solid also delivered double-digit growth, driven by strong demand for capsule-filling solutions and an expanded granulation product portfolio.
The company said the Pharma performance reflects its customer-centric approach under its lifecycle partner strategy, with new solutions contributing to significant new customer wins. In the Pharma and Biotech industry, Europe remained a resilient core market. In Asia, Pharma sales rose substantially year-on-year, with the company citing further market share gains in the expanding biologics market and benefits from its operations in China. In the United States, Pharma order intake increased significantly, which the company attributed to its focused growth strategy for the region.
Food business growth muted by challenging market dynamics
Market dynamics remained challenging in the first half of 2026, particularly in the Chocolate & Bars industry, where Syntegon holds the position of global market leader according to the company. Customers continued to face cost pressure, leading to cautious investment decisions. Against this backdrop, Syntegon launched new product solutions aimed at supporting customers’ need for higher efficiency and flexibility in the first half. The company said the value of these solutions is reflected in customers’ increasing adoption of the SVX platform, a vertical packaging solution. In response to the more challenging market dynamics, the company stated it is taking measures to address the market challenges and defend its margin position.
Innovation addresses the needs of the ‛Factory of the Future’
The company said customers increasingly seek more automated, flexible and efficient production as they respond to labor shortages, cost pressure, stricter regulations and growing portfolio complexity. In the first half, Syntegon launched next-generation solutions with enhanced automation, robotics and AI-enabled functionality, which the company said support customers in developing their ‘Factory of the Future’. Combined with Syntegon’s lifecycle services, the company said customers achieve the lowest total cost of ownership across their operational footprint.
Syntegon confirms full-year 2026 outlook of growth and margin expansion
For the full year 2026, Syntegon confirmed its outlook. Citing a healthy order book, sustained market demand in Pharma and Biotech, and a continued focus on disciplined execution, the company said it expects further profitable growth in 2026.